Podcasts about barts cancer institute

In this episode of Hema Now, Diu Nguyen joins Jonathan Sackier to discuss breakthroughs in acute myeloid leukaemia (AML) research. From RNA-binding proteins to the future of stem cell-targeted therapies, Nguyen shares the translational goals of her lab and what's on the horizon in AML diagnosis and treatment.    Timestamps:  01:20 – Quickfire Insights  03:32 – AML Breakthroughs  04:47 – Leukaemia Surprise  06:42 – Alternate Pathways  07:54 – RNA Differences  12:08 – Diagnostics Future  14:03 – RBMX Spotlight  20:21 – Targeted Therapies  27:07 – Treatment Barriers  31:32 – Three Wishes 

In this episode of Hema Now, Jonathan Sackier is joined by John Riches, Clinical Reader in Cancer Immunometabolism at the Barts Cancer Institute and Honorary Consultant Haemato-oncologist. They explore how metabolic shifts drive lymphoma progression, the potential of immunotherapy, and what the future holds for treating lymphoid malignancies.  Timestamps:      00:00 – Introduction  01:46 – Riches' journey into haematology  03:42 – What is T cell exhaustion?  07:06 – The key role of metabolism in lymphoma  09:33 - Richter's syndrome  13:17 – Breakthroughs in immunotherapy  20:27 – The challenges of translational research  25:39 – B cells in autoimmune diseases  28:16 – The potential of breath biopsy  32:58 – Riches' three wishes for healthcare 

Dr Joyce O'Shaughnessy from Sarah Cannon Research Institute in Dallas, Texas, Dr Mark D Pegram from Stanford Cancer Institute in California, and Prof Peter Schmid from Barts Cancer Institute in London, United Kingdom, summarize currently available data guiding treatment decision-making for patients with low and ultralow HER2 expression and present cases from their practices. CME information and select publications here.

Dr Joyce O'Shaughnessy from Sarah Cannon Research Institute in Dallas, Texas, Dr Mark D Pegram from Stanford Cancer Institute in California, and Prof Peter Schmid from Barts Cancer Institute in London, United Kingdom, summarize currently available data guiding treatment decision-making for patients with low and ultralow HER2 expression and present cases from their practices. CME information and select publications here.

Patients with muscle-invasive bladder cancer experienced “clinically meaningful” improvements in key outcomes—event-free survival and overall survival—when the immune checkpoint inhibitor durvalumab was added to their standard neoadjuvant chemotherapy. This was in research findings, reported at the ESMO Congress 2024, from the NIAGARA randomized Phase Ill trial of neoadjuvant durvalumab plus chemotherapy followed by radical cystectomy and adjuvant durvalumab in patients with cisplatin-eligible muscle-invasive bladder cancer. After his talk at the ESMO Barcelona conference, first author Thomas Powles, MBBS, MRCP, MD, from the Barts Cancer Institute at Queen Mary University of London, UK, met up with Oncology Times correspondent Peter Goodwin.

The Gut 360 Podcast  Episode 18: Women's Health, Cycle Syncing and Why Your Health Doesn't Need To Be Complicated with Dr Frankie Jackson-Spence Topics Discussed: The 4 pillars of health  Simple ways to improve your diet, exercise, sleep and stress Why you need to avoid an all-or-nothing mentality Differences between men and women's needs for diet, exercise and sleep   What does ‘women's health' actually mean What you need to know about cycle syncing How to eat in tune with the phases of our cycle What to eat in the follicular phase Nutrition to support the luteal phase How to support hormone health with lifestyle practices Why healthy fats are essential for our hormone health Can you eat to reduce PMS How to ‘do it all' and how Frankie finds balance Productivity hacks for busy people  Find Eli Brecher here: LinkedIn | Eli Brecher Eli Brecher Nutrition Website | www.elibrecher.co.uk Eli Brecher Instagram | @elibrechernutrition Subscribe to Eli's Newsletter: www.subscribepage.io/join-my-inner-circle Recipe Of The Week: https://elibrecher.co.uk/stewed-apples/ https://elibrecher.co.uk/crumble/ Find Dr Frankie here: Instagram | @drfrankiejs Vision of Health Podcast Dr Frankie Jackson-Spence is a medical Doctor, media and content creator and podcast host, who offers factual and relatable health advice in preventative medicine.    A qualified doctor working in cancer research, Dr Frankie graduated with a degree in Medicine and Surgery with distinction in 2018. During this time, Dr Frankie set out to better understand the risk factors for cancer, becoming involved in clinical trials and drug development at Barts Cancer Institute for Renal and Bladder cancer, currently undertaking her PhD in bladder cancer.   Alongside her full time medical and academic work she is also a qualified PT and runs an educational social media page @drfrankiejs, where she promotes evidence-based lifestyle medicine, advocates for women's health and busts the common health myths. She is the host of health podcast Vision of Health, has a column in The Telegraph and makes regular TV appearances to disseminate her knowledge, becoming an enthusiastic public speaker for general preventative health.  _____________________________________________________________________________________ About The Gut 360 Podcast Welcome to The Gut 360 Podcast with Eli Brecher, a Registered Associate Nutritionist with a passion for gut health. This podcast will provide nutrition tips, mindset tools and actionable steps to help you thrive on your journey to a healthier gut and a happier you. The mission of this podcast is to empower you to optimise your nutrition and transform your gut health using a 360° approach to wellbeing, so that you can reclaim your life and unlock your full potential.

Prof Peter Schmid from the Barts Cancer Institute in London, United Kingdom, and Dr Sara Tolaney from the Dana-Farber Cancer Institute in Boston, Massachusetts, review clinical trials investigating the role of antibody-drug conjugate-mediated therapies in the treatment of metastatic breast cancer. CME information and select publications here (https://www.researchtopractice.com/InsideTheIssue2024/ADCsmBC)

Prof Peter Schmid from the Barts Cancer Institute in London, United Kingdom, and Dr Sara Tolaney from the Dana-Farber Cancer Institute in Boston, Massachusetts, review clinical trials investigating the role of antibody-drug conjugate-mediated therapies in the treatment of metastatic breast cancer.

Dr Rana R McKay from Moores Cancer Center in La Jolla, California, and Prof Thomas Powles from Barts Cancer Institute in London, United Kingdom, discuss recent updates on available and novel treatment strategies for renal cell carcinoma.

Dr Rana R McKay from Moores Cancer Center in La Jolla, California, and Prof Thomas Powles from Barts Cancer Institute in London, United Kingdom, discuss recent updates on available and novel treatment strategies for renal cell carcinoma, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here. (https://www.researchtopractice.com/PostASCO2024/RCC)

A mathematical model using data from routine diagnostic samples has been found to accurately predict individual patient responses to the main candidate first-line treatments for acute myeloid leukemia. Findings from a validation study in independent patient cohorts led by researchers from the Barts Cancer Institute at the Queen Mary University of London were reported at a poster session of the 2024 ASCO Annual Meeting. Oncology Times correspondent Peter Goodwin attended the session and talked with the second author of the study, Weronika E. Borek PhD, a Bioinformatics Technical Lead at Kinomica Limited in London.

Dr Shilpa Gupta from the Taussig Cancer Institute in Cleveland, Ohio, and Prof Thomas Powles from the Barts Cancer Institute in London, United Kingdom, discuss clinical decision-making with numerous treatment strategies for urothelial bladder cancer, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/YiR2023/Bladder).

Dr Shilpa Gupta from the Taussig Cancer Institute in Cleveland, Ohio, and Prof Thomas Powles from the Barts Cancer Institute in London, United Kingdom, discuss clinical decision-making with numerous treatment strategies for urothelial bladder cancer.

Topic discussing: Can eliminating extra chromosomes in cancer cells prevent tumour growth? Can bladder disease be treated by medical microrobots? And What is the significance of the Jalsa Salana Presenter: Daniyal Ahmad Nafeez Qamar Can Eliminating extra chromosomes in cancer cells prevent tumour growth? Gist of the story: Cancer cells with extra chromosomes depend on those chromosomes for tumor growth, a new study reveals, and eliminating them prevents the cells from forming tumours. The findings, said the researchers, suggest that selectively targeting extra chromosomes may offer a new route for treating cancer Can bladder disease be treated by medical microrobots? Gist of the story: Engineers have designed a new class of 'microrobots' several times smaller than the width of a human hair that may be able to treat human illnesses like interstitial cystitis -- a painful bladder disease that affects millions of Americans. What is the significance of the Jalsa Salana Jalsa Salana is the formal, annual gathering of the Ahmadiyya Muslim Community initiated by Hazrat Mirza Ghulam Ahmad, founder of the community usually, the gathering spans over three days, beginning on Friday with the Friday Sermon. Guest: Dr Sarah McClelland- Lecturer at the Barts Cancer Institute, Queen Mary University of London. Ased Ali- NHS Consultant Urological Surgeon working in Yorkshire and also Medical Director at a MedTech company called Convatec. Arslan Ahmad- A volunteer of Jalsa Salana Waqfe Arzi Team (Short Term Dedication Team) Researchers: Dania Nasir Produced by: Dania Nasir

Dr Frankie is an NHS Doctor, media and content creator who offers factual and relatable health advice in preventative medicine. A qualified doctor working on the frontline, Dr Frankie graduated with a degree in Medicine and Surgery in 2018. During this time, Dr Frankie set out to better understand the risk factors for cancer, becoming heavily involved in clinical trials at Barts Cancer Institute for Renal and Bladder cancer. Alongside all of this whilst juggling university, Dr Frankie started an educational social media page to provide expertise on a range of health and wellbeing topics. In her well-known #MedicalMonday, Frankie posted a weekly poll on her Instagram to allow people to ask health-related questions, each time focusing on a different topic. Frankie's profile in this space began to grow, and as a result Frankie now also makes regular appearances to disseminate her knowledge, becoming an enthusiastic public speaker for general preventative health. Although there are many things I'd love to discuss with Dr Frankie, today we share a conversation about training, nutrition and the female menstrual cycle,. The episode covers the entire cycle story, exploring what a ‘normal cycle' looks like, when ovulation occurs, and how to identify important changes that sometimes signal significant health problems. Dr Frankie also discusses how a women's strength may be affected by constantly changing hormone levels, and how we can adjust our training and nutrition to reach our full potential at any point in our cycle. This episode is important for both men and women, so if you're a female (or know one), I strongly recommend you listen...- When you should be concerned about your periods?!- 3 essential things women should do to live a healthier life- Can training on your period help with menstrual cramps?- Why you should track your period if you work out- How do we know when we can push ourselves harder when we work out on our periods?- Should we replace the iron we lose during our period?- Why you need to eat before working out Hosted on Acast. See acast.com/privacy for more information.

Onderzoekers zijn een trucje op het spoor gekomen, waarmee het agressieve huidkankercellen lukt om ook naar andere delen van het lichaam te verspreiden. De volgende stap: kijken hoe we dit mechanisme eens goed in de weg kunnen gaan zitten.  In deze audio hoor je onderzoekers Victoria Sanz-Moreno van het Queen Mary's Barts Cancer Institute en Jeremy Carlton from King's College London en The Francis Crick Institute. Lees hier meer over het onderzoek: Researchers identify protein that helps skin cancer spread throughout the body. De paper vind je in Nature: LAP1 supports nuclear adaptability during constrained melanoma cell migration and invasion. See omnystudio.com/listener for privacy information.

Neobe Therapeutics is an early-stage startup engineering safe recombinant bacterial products to enable immune infiltration in solid tumors. Their bacterial products combine innate tumor colonization with genetically engineered inducible biosensors to disrupt tumor microenvironment barriers to infiltration. By enabling successful infiltration of immune excluded tumors using our bacterial products they will be able to multiply the number of patients that respond to existing immunotherapies, with a focus on checkpoint inhibitors. Neobe was formed in January 2021 in London, UK with the support of Deep Science Ventures and Cancer Research UK. The founding team is made up of Dr. Pedro Correa de Sampaio, a cancer biologist with a successful career studying the tumor microenvironment in top academic institutions in the UK and the US; and Dr. Annelise Soulier, a microbiologist and molecular biologist with several years of experience engineering bacteria for therapeutic applications in one of the top UK companies in the field, having authored patents in the field and developed products that are currently in clinical trials. The founding team has the support of a world class advisory board, including top academic researchers and former C-level industry executives in the field. It was selected for the 2021 cohort of the highly prestigious Accelerate@Babraham in Cambridge, UK, won the London branch of the Imagine IF! healthcare startup competition and Neobe's co-founder Annelise Soulier was a finalists of the AIM-HI Women's Venture Competition. During its first year, Neobe developed the genetic tools necessary for the generation of its initial prototype, and established collaborations with top academic institutions such as the Barts Cancer Institute to initiate efficacy studies. Neobe was also recently awarded a collaborative Innovate UK Biomedical Catalyst grant, from the UK government, for the development of its second product at a total project cost of £505K.

Learn about the most recent information released at the annual San Antonio Breast Cancer Symposium regarding metastatic breast cancer research with Dr. Peter Schmid, Professor of Cancer Medicine at Barts Cancer Institute in London, England. Dr. Schmid will provide a comprehensive update and answer your questions about these new developments.More info is available on our website www.ourmbclife.orgBe sure to rate, review us, and sign up for our newsblast.Got something to share? Feedback? Email:  Ourmbclife@sharecxancersupport.orgSend us a voice recording via email or through speakpipe on our website.Follow on Facebook, Instagram, and Twitter @ourmbclife

Have you ever wondered what it's like to take part in a clinical trial? It's one of those things we hear about taking place but we don't really find out what goes on, unless we get invited to take part. Today you'll hear from Hemant Kocher who is a professor of Liver and Pancreas Surgery at Barts Cancer Institute & Queen Mary University of London, and Consultant Pancreatic and Liver Surgeon at Barts Health NHS Trust. He tells us what it's like to be part of a clinical trial as well as explaining the research he's working on when it comes to beating Pancreatic Cancer. You can follow these hashtags #Sethslegacy and #30PRPodcasts as well as #ShineASpotlight4Seth and #Sparkle4Seth You can find out more about Purple Rainbow herehttps://purplerainbow.co.uk/ ( https://purplerainbow.co.uk/) Music Credithttps://www.purple-planet.com/ ( Purple Planet Studios) DISCLAIMER: All views, information or opinions expressed in this podcast series are solely my own and those of individuals interviewed and do not necessarily represent the views and opinions of Pancreatic Cancer UK , Pancreatic Cancer Action, Pancreatic Cancer Research Fund And The Elizabeth Coteman Fund  The charities and their employees are not responsible for and do not verify the accuracy of any of the information contained in the podcast series. The primary purpose of this podcast series is to inform, but it does not constitute medical or other professional advice or services.

In this episode we are joined by Dr Alison Berner, Clinical Research Fellow in Medical Oncology & Specialty Doctor in Gender Identity Medicine at Barts Cancer Institute, Queen Mary University of London and the Tavistock and Portman NHS Foundation Trust, London, UK. Paper: Attitudes of trans men and non-binary people to UK cervical screening https://doi.org/10.3399/BJGP.2020.0905 (https://doi.org/10.3399/BJGP.2020.0905) The UK's National Health Service cervical screening program has contributed to a 70% reduction in the cervical cancer mortality since 1988. Trans men and non-binary people assigned female at birth (TMNB) experience barriers to accessing adequate cervical screening and are less likely to engage in screening than cisgender women but the attitudes, experiences and behaviours of TMNB as they relate to cervical screening remain unexplored in a UK context. This study indicates that TMNB lack sufficient information about cervical screening and experience barriers to accessing screening services at personal, interpersonal and institutional levels. Cervical screening uptake could be increased by adopting TMNB-appropriate screening invitations, providing options for self-sampling, improving cultural sensitivity in health literature, and improving access to trans-specific or trans-aware health services.

In the fifty-sixth episode of the Just Checking In Podcast we checked-in with Lottie Swinyard. Lottie is a Vent Champion and PHD Cancer Researcher at Barts Cancer Institute. Lottie's academia journey, grief, anxiety and recovery are all on the menu for this episode. As always, #itsokaytovent You can read the article Lottie wrote on Vent about her Dad here: https://vent.org.uk/double-whammy-dealing-loss-studying You can follow Lottie on social media below: Instagram: https://www.instagram.com/smileyscientist/ Music: @patawawa - Strange: www.youtube.com/watch?v=d70wfeJSEvk TRIGGER WARNING: this podcast contains a deep discussion about grief and loss which some listeners may find distressing or upsetting, so please listen with caution.

Breast cancer is a leading cause of death in women. Some women have a cancer susceptibility gene known as BRCA, and women should be tested for BRCA under some circumstances. Carol Mangione, MD, division chief of General Internal Medicine and Health Services Research at UCLA, discusses when testing is appropriate, and Ranjit Manchanda, MD, PhD, from Barts Cancer Institute in London, UK, discusses the cost-effectiveness of BRCA screening for women who have had breast cancer.

For this episode of SC@L digested, PhD student Inês Tomás interviews Dr Trevor Graham from the Barts Cancer Institute about his career path, fusing mathematics and biology, difficulties in modelling cancer, and the hunt for the cure…. for more information about his research follow this link:https://www.bci.qmul.ac.uk/staff/item/trevor-graham

On this episode of Sequenced, Dr. Ranjit Manchandra, Clinical Senior Lecturer at Barts Cancer Institute in London, sits down with Business Insider’s Erin Brodwin to discuss population-based genetic testing for cancer prevention. Dr. Manchandra’s recent research found that population testing for multiple breast cancer genes has the potential to be both cost-effective and life-saving.

Prof Gribben (Queen Mary University of London and Barts Cancer Institute, London, UK), Prof Stilgenbauer (University of Ulm, Ulm, Germany), Dr Tedeschi (Azienda Ospedaliera Niguarda Cà Granda Milano, Milano, Italy) and Dr Thornton (Royal College of Surgeons, Dublin, Ireland) discuss the latest data on chronic lymphocytic leukaemia from ASH 2015. The experts cover the RESONATE-2 trial, which compared ibrutinib versus chlorambucil in the treatment of elderly patients who had not received any prior treatment. Efficacy and tolerance data from the trial are set to have a significant impact on CLL treatment for the elderly, it is observed. The panel also discuss data on venetoclax, an oral, targeted drug that inhibits Bcl-2 - a protein that regulates natural cell death. This new agent is a promising option for the very difficult-to-treat CLL patient population characterised by the presence of the 17p deletion. The GREEN study is also mentioned by the panel. This trial studied the combined effects of the glycoengineered type II anti-CD20 monoclonal antibody obinutuzumab with bendamustine in treatment naiive CLL. Finally the panel talks about risk stratification and using known pathways to stratify patients in combination with individual patient characteristics.

Prof John Gribben (Queen Mary University of London and Barts Cancer Institute, London, UK) and Prof Stephan Stilgenbauer (University of Ulm, Ulm, Germany) discuss the latest advances in the treatment of chronic lymphocytic leukaemia (CLL) presented at ASH 2015 and share their opinions on treatment selection and considerations for different patients. Ibrutinib has previously been largely used as a treatment for high-risk patients with refractory CLL but data from the RESONATE-2 trial presented at the meeting by Dr Alessandra Tedeschi (Azienda Ospedaliera Niguarda Cà Granda, Milano, Italy) suggests that earlier use of the drug in treatment-naïve patients would also be of benefit.

Earlier this week, the US space agency successfully put a new probe in orbit around Jupiter. The Juno satellite, which left Earth five years ago, had to fire a rocket engine in a tricky and precise manoeuvre in order to brake and become ensnared by Jupiter's gravity. Fran Baganal is a mission scientist for Juno and tells Adam Rutherford what measurements Juno is now in position to make. Space is full of junk left over from past space missions: from flecks of paint to used rockets, dead satellites, also debris from past collisions of space junk. This junk is speeding around the Earth at several thousand miles per hour. At those speeds even small pieces of rubbish just fractions of a millimetre across can damage communication satellites which are vital for the web, mobile phones, and satellite navigation on earth. The Surrey Space centre team are preparing to launch the world's first space litter-picking mission. The RemoveDebris team share their clean up designs with Adam. Researchers have had success growing body parts like windpipes and ears in the laboratory for use in transplants. A group of scientists at Barts Cancer Institute in London are making own tumours; tissues we don't want. However, it is important to study how they grow, and co-opt other cells in the body. Reporter Anand Jagatia heads to their tissue lab to see what they've grown. All animals take risky decisions all the time. The ability to assess the potential gain from the potential harm, and make the right choice, gives the animal an evolutionary advantage. A new study suggests that plants are capable of making similar calculations, despite not having brains. Alex Kacelnik at Oxford University is one of the scientists behind the experiment that suggests that pea plants are willing to gamble. Presenter: Adam Rutherford Producer: Adrian Washbourne.

This podcast is part of a series for patients who have just been diagnosed with a specific genitourinary, or GU cancer. In this series, Dr. Charles Ryan, a medical oncologist and professor who specializes in the genitourinary tract at the UCSF Helen Diller Family Comprehensive Cancer Center, speaks with experts on specific GU cancers to shed light on what happens after an initial diagnosis. Today’s guest is Dr. Thomas Powles, clinical professor of genitourinary oncology at Barts Cancer Institute in London. In this podcast, Dr. Ryan and Dr. Powles discuss what happens after a diagnosis of metastatic bladder cancer, including new advances in immunotherapy for bladder cancer. Cancer Basics